- Title: Subtitle
- PCSK9 inhibitor alirocumab as add-on to atorvastatin versus other lipid treatment strategies in patients at high CVD risk: ODYSSEY OPTIONS I
- Creators
- Harold BaysDaniel GaudetRobert WeissJuan Lima RuizGerald F WattsIoanna Gouni-BertholdJennifer G RobinsonJian ZhaoCorinne HanotinStephen Donahue
- Resource Type
- Abstract
- Publication Details
- Circulation (New York, N.Y.), Vol.130(Suppl_2)
- Publisher
- Lippincott Williams & Wilkins, WK Health
- DOI
- 10.1161/circ.130.suppl_2.16194
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Language
- English
- Date published
- 11/25/2014
- Description audience
- Professional
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984364386902771
Abstract
PCSK9 inhibitor alirocumab as add-on to atorvastatin versus other lipid treatment strategies in patients at high CVD risk: ODYSSEY OPTIONS I
Circulation (New York, N.Y.), Vol.130(Suppl_2)
11/25/2014
DOI: 10.1161/circ.130.suppl_2.16194
Abstract
Details
Metrics
16 Record Views